Zelnorm

Zelnorm, with the generic name tegaserod, is a medication that was primarily used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women under the age of 65. It belongs to a class of drugs known as selective serotonin 5-HT4 receptor agonists. By stimulating these receptors in the gut, Zelnorm was believed to increase intestinal motility and secretion, thereby relieving constipation and abdominal pain associated with IBS-C.

The drug was approved by the U.S. Food and Drug Administration (FDA) in 2002. However, its use was later restricted due to concerns about potential cardiovascular side effects. Reports of serious cardiac events, including heart attack and stroke, led to its voluntary withdrawal from the market in 2007. Following a review of further data, the FDA allowed for a limited reintroduction in 2009, restricting its use to a smaller patient population with severe IBS-C or CIC who had not responded to other treatments, and with strict precautions.

Zelnorm was available as an oral tablet. Common side effects reported during its use included diarrhea, nausea, abdominal pain, and headache. Due to the cardiovascular risks, physicians were advised to carefully weigh the potential benefits against the risks before prescribing Zelnorm, and patients were monitored for any signs of cardiac issues. The drug's availability and indications have been subject to ongoing evaluation by regulatory agencies.